| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 12, 2024 | ANIP Ani Pharmaceuticals Inc | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 250 | $64.91 | $16,227.50 | -0.4% | -13.2% | +2.3% | |
| Jul 12, 2024 | TKNO Alpha Teknova, Inc. | Lowell Matthew50 | Chief Financial Officer | Buy | 40,322 | $1.24 | $49,999.28 | +45.8% | +277.3% | +275.8% | |
| Jul 12, 2024 | TKNO Alpha Teknova, Inc. | Gunstream Stephen47 | President And CEO | Buy | 80,645 | $1.24 | $99,999.80 | +49.5% | +277.3% | +275.8% | |
| Jul 12, 2024 | LQDA Liquidia Corp | Kaseta Michael57 | CFO And COO | Sell | 3,906 | $12.53 | $48,942.18 | -1.2% | -12.5% | +11.7% | |
| Jul 12, 2024 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 1,528 | $12.53 | $19,145.84 | -1.0% | -12.5% | +11.7% | |
| Jul 12, 2024 | LQDA Liquidia Corp | Schundler Russell58 | General Counsel | Sell | 1,985 | $12.53 | $24,872.05 | -0.4% | -12.5% | +11.7% | |
| Jul 12, 2024 | LQDA Liquidia Corp | Saggar Rajeev | Chief Medical Officer | Sell | 1,470 | $12.53 | $18,419.10 | -0.7% | -12.5% | +11.7% | |
| Jul 12, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $325.46 | $2,343,345.55 | -30.0% | +10.3% | -8.0% | |
| Jul 12, 2024 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 1,146 | $12.53 | $14,359.38 | -1.0% | -12.5% | +11.7% | |
| Jul 11, 2024 | ETST Earth Science Tech, Inc. | Tabraue Mario Guillermo | COO | Buy | 20,000 | $0.25 | $4,980.00 | +0.2% | - | - | |
| Jul 10, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $939.82 | $197,361,397.77 | - | -2.8% | -15.9% | |
| Jul 10, 2024 | LNTH Lantheus Holdings, Inc. | Pruden Gary J | Director | Sell | 12,530 | $95.04 | $1,190,851.20 | -51.1% | +1.8% | -21.0% | |
| Jul 10, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $324.54 | $2,336,704.42 | -21.5% | +8.1% | -8.8% | |
| Jul 9, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,335 | $20.28 | $47,353.80 | -1.4% | -6.0% | +147.7% | |
| Jul 9, 2024 | HIMS Hims & Hers Health, Inc. | Baird Melissa | Chief Operating Officer | Sell | 52,875 | $20.61 | $1,089,827.78 | -2.9% | -6.0% | +147.7% | |
| Jul 8, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 93,593 | $918.64 | $85,977,953.61 | - | -2.1% | -15.3% | |
| Jul 8, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $315.15 | $2,269,085.39 | -35.8% | +10.4% | -7.1% | |
| Jul 5, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 52,369 | $915.18 | $47,927,193.52 | - | -3.2% | -15.5% | |
| Jul 5, 2024 | BIOE Bio Essence Corp | Yan Yin | Chief Executive Officer | Sell | 60,274 | $8.03 | $484,286.11 | -0.1% | - | - | |
| Jul 3, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 333,332 | $20.72 | $6,907,499.58 | -22.0% | -5.8% | +134.2% | |
| Jul 3, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 8,848 | $915.31 | $8,098,654.51 | - | -1.5% | -13.1% | |
| Jul 3, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $315.35 | $2,270,542.22 | -29.6% | +15.0% | -5.3% | |
| Jul 2, 2024 | PCRX Pacira Biosciences, Inc. | Slonin Jonathan72 | Chief Medical Officer | Sell | 2,836 | $28.25 | $80,117.00 | -2.9% | -33.8% | +2.1% | |
| Jul 1, 2024 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 272 | $138.11 | $37,565.92 | -3.5% | -17.8% | -8.6% | |
| Jul 1, 2024 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 10,000 | $140.19 | $1,401,864.00 | -35.5% | -17.8% | -8.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.